Dormant Mycobacterium tuberculosis converts isoniazid to the active drug in a Wayne’s model of dormancy.
- Published in:
- Journal of Antibiotics, 2018, v. 71, n. 11, p. 939, doi. 10.1038/s41429-018-0098-z
- By:
- Publication type:
- Article
Works matching IS 00218820 AND DT 2018 AND VI 71 AND IP 11
Results: 9
1
2
Evaluation of LL-37 antimicrobial peptide derivatives alone and in combination with vancomycin against S. aureus.
- Published in:
- Journal of Antibiotics, 2018, v. 71, n. 11, p. 971, doi. 10.1038/s41429-018-0090-7
- By:
- Publication type:
- Article
3
Pullusurfactans A-E, new biosurfactants produced by Aureobasidium pullulans A11211-4-57 from a fleabane, Erigeron annus (L.) pers.
- Published in:
- Journal of Antibiotics, 2018, v. 71, n. 11, p. 920, doi. 10.1038/s41429-018-0089-0
- By:
- Publication type:
- Article
4
Novel desferrioxamine derivatives synthesized using the secondary metabolism-specific nitrous acid biosynthetic pathway in Streptomyces davawensis.
- Published in:
- Journal of Antibiotics, 2018, v. 71, n. 11, p. 911, doi. 10.1038/s41429-018-0088-1
- By:
- Publication type:
- Article
5
Aplasmomycin and boromycin are specific inhibitors of the futalosine pathway.
- Published in:
- Journal of Antibiotics, 2018, v. 71, n. 11, p. 968, doi. 10.1038/s41429-018-0087-2
- By:
- Publication type:
- Article
6
Acremotins A-D, peptaibiotics produced by the soil-derived fungus Acremonium persicinum SC0105.
- Published in:
- Journal of Antibiotics, 2018, v. 71, n. 11, p. 927, doi. 10.1038/s41429-018-0086-3
- By:
- Publication type:
- Article
7
Pyroxazone, a new neuroprotective compound from Streptomyces sp. RAN54.
- Published in:
- Journal of Antibiotics, 2018, v. 71, n. 11, p. 962, doi. 10.1038/s41429-018-0085-4
- By:
- Publication type:
- Article
8
Quinohemanine, a quinoxalinone-bohemamine hybrid compound from Streptomyces sp. CPCC 200497.
- Published in:
- Journal of Antibiotics, 2018, v. 71, n. 11, p. 965, doi. 10.1038/s41429-018-0084-5
- By:
- Publication type:
- Article
9
5-Aminosalicylic acid downregulates the growth and virulence of Escherichia coli associated with IBD and colorectal cancer, and upregulates host anti-inflammatory activity.
- Published in:
- Journal of Antibiotics, 2018, v. 71, n. 11, p. 950, doi. 10.1038/s41429-018-0081-8
- By:
- Publication type:
- Article